| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-05-22 | NCT07601607 Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell… | Phase 1/2 | Not Yet Recruiting |
| 2026-05-20 | NCT07597941 Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia… | Phase 2/3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia… | Acute Promyelocytic Leukemia (APL) | Not Yet Recruiting |
| Phase 2 | |||
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia | Recruiting |
| NCT07459608 | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent… | Indolent Lymphoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT04501120 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients… | Relapsed/Refractory Acute Myeloid Leukaemia | Recruiting |
| NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | Diffuse Large B Cell Lymphoma (DLBCL) | Not Yet Recruiting |
| NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell… | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Not Yet Recruiting |
| Phase 1 | |||
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |